x
x
Disclaimer

The U.S. section of Abbottep.com is a product-specific website that is NOT intended for non U.S. residents. This web content is exclusively reserved for health care professionals in the United States.

Do you wish to continue to visit the Abbottep.com U.S. section?

Get your rhythm back.

Serious heart rhythm disorders called arrhythmias, affect the lives of millions of people daily. Unfortunately, most treatments for these conditions are generic and one-size-fits-all, with mixed results.


But there’s hope.


We believe there is a better way to treat serious heart rhythm disorders such as atrial fibrillation and ventricular tachycardia. Using Abbott Electrophysiology’s technology, doctors can identify the sources of arrhythmias that are unique to each person. Now treatment can be tailored to your individual needs.


Find Your Source.
Get Tailored Therapy.
Get Your Rhythm Back.

Find a doctor near you who is using the Topera Rotor Mapping System

The most common heart rhythm disorder, atrial fibrillation (AF, or afib) is a serious global public health problem which affects millions of people around the world. If left untreated, AF doubles the risk of heart-related deaths and also increases stroke risk by up to 500%. Unfortunately, although it is such a serious health problem, AF has historically been difficult to treat with an acceptable degree of success.

In response to this unaddressed need, Abbott, Inc. has developed a unique 3D analysis and mapping solution (the Abbott 3D Mapping System), which consists of the RhythmView Workstation and FIRMap diagnostic catheter. The Abbott 3D Mapping System has been designed to enable physicians to view the electrical activity of the heart, thereby supporting the diagnosis and patient-specific treatment planning for a variety of heart arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia.

The Abbott 3D Mapping System received FDA clearance in 2013 and is now in routine use at several leading medical centers throughout the United States.

Three Year CONFIRM Follow-up

CONFIRM Trial Extended Follow-Up 1


study5

Study Objectives

The aim of this study was to determine if coronary ablation procedures that target patient-specific atrial fibrillation (AF)-sustaining substrates known as rotors or focal sources, is more durable than trigger ablation alone at preventing late AF recurrence.

Background

Late recurrence substantially limits the efficacy of pulmonary vein isolation (PVI) for AF and is associated with pulmonary vein reconnection and the emergence of new triggers.

Methods

The study was a 3 year follow-up of the CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial2, in which 92 consecutive patients with AF (70.7% persistent) underwent novel computational mapping. Ablation comprised source (focal impulse and rotor modulation or FIRM) and then conventional ablation in 27 patients (FIRM-guided) and conventional ablation alone in 65 patients (FIRM-blinded). Patients were followed with implanted electrocardiographic monitors when possible (85.2% of FIRM-guided patients, 23.1% of FIRM-blinded patients).

Conclusions

FIRM-guided ablation is more durable than conventional trigger-based cardiac ablation procedures in preventing 3-year AF recurrence. The authors recommended that future studies should investigate how ablation of patient-specific AF-sustaining rotors and focal sources alters the natural history of arrhythmia patients.


  1. Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani G, Krummen DE, Shivkumar K, Miller JM, Ablation of Rotor and Focal Sources Reduces Late Recurrence of Atrial Fibrillation Compared to Trigger Ablation Alone, J Am Coll of Cardiol (2014), doi: 10.1016/j.jacc.2014.02.543.
  2. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel W-J, and Miller JM. Treatment of Atrial Fibrillation by the Ablation of Localized Sources-CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) Trial. J Am Coll Cardiol 2012; 60(7):628-3

 

These trials were supported by grants to the lead author from the National Institutes of Health and the Doris Duke Charitable Foundation. Please refer to the study citations to review all reported author conflicts of interest.